Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody a phase I trial in patients with systemic lupus erythematosus.docVIP

Available online /content/10/5/R109 Research article Open Access Vol 10 No 5 Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus Richard Furie1, William Stohl2, Ellen M Ginzler3, Michael Becker4, Nilamadhab Mishra5, Winn Chatham6, Joan T Merrill7, Arthur Weinstein8, W Joseph McCune9, John Zhong10, Wendy Cai11, William Freimuth12 for the Belimumab Study Group 1Division of Rheumatology and Allergy-Clinical Immunology, North Shore Long Island Jewish Health System, Marc